Telomir Pharmaceuticals (TELO) Competitors $4.69 -0.10 (-2.09%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends TELO vs. ALT, PROK, MNMD, STOK, ARCT, RNAC, MLYS, VERV, MGTX, and SAGEShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Altimmune (ALT), ProKidney (PROK), Mind Medicine (MindMed) (MNMD), Stoke Therapeutics (STOK), Arcturus Therapeutics (ARCT), Cartesian Therapeutics (RNAC), Mineralys Therapeutics (MLYS), Verve Therapeutics (VERV), MeiraGTx (MGTX), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Altimmune ProKidney Mind Medicine (MindMed) Stoke Therapeutics Arcturus Therapeutics Cartesian Therapeutics Mineralys Therapeutics Verve Therapeutics MeiraGTx Sage Therapeutics Altimmune (NASDAQ:ALT) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Does the MarketBeat Community prefer ALT or TELO? Altimmune received 57 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformAltimmuneOutperform Votes5773.08% Underperform Votes2126.92% Telomir PharmaceuticalsN/AN/A Do analysts rate ALT or TELO? Altimmune currently has a consensus target price of $19.71, indicating a potential upside of 187.38%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Telomir Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Altimmune 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ALT or TELO more profitable? Telomir Pharmaceuticals has a net margin of 0.00% compared to Altimmune's net margin of -199,076.92%. Altimmune's return on equity of -55.81% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Altimmune-199,076.92% -55.81% -50.60% Telomir Pharmaceuticals N/A -1,087.92%-806.34% Do institutionals & insiders have more ownership in ALT or TELO? 78.1% of Altimmune shares are held by institutional investors. 4.1% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings & valuation, ALT or TELO? Telomir Pharmaceuticals has lower revenue, but higher earnings than Altimmune. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAltimmune$430K1,134.61-$88.45M-$1.55-4.43Telomir PharmaceuticalsN/AN/A-$13.07MN/AN/A Does the media favor ALT or TELO? In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Altimmune. MarketBeat recorded 1 mentions for Telomir Pharmaceuticals and 0 mentions for Altimmune. Telomir Pharmaceuticals' average media sentiment score of 0.47 beat Altimmune's score of 0.10 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Altimmune Neutral Telomir Pharmaceuticals Neutral SummaryAltimmune beats Telomir Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$138.87M$6.50B$5.34B$9.12BDividend YieldN/A2.95%5.37%4.01%P/E RatioN/A4.3657.4613.13Price / SalesN/A310.771,272.2275.82Price / CashN/A22.8736.6632.72Price / BookN/A4.964.884.58Net Income-$13.07M$154.90M$118.05M$224.83M7 Day Performance2.40%1.35%1.45%2.37%1 Month Performance-9.46%0.41%2.50%4.40%1 Year PerformanceN/A3.08%25.79%20.10% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir PharmaceuticalsN/A$4.69-2.1%N/AN/A$138.87MN/A0.001ALTAltimmune2.296 of 5 stars$6.78-1.3%$19.71+190.8%-25.8%$482.23M$52,000.00-4.3750PROKProKidney2.1366 of 5 stars$1.65+1.9%$4.50+172.7%+27.7%$481.24MN/A-3.003Positive NewsMNMDMind Medicine (MindMed)2.1226 of 5 stars$6.49-6.3%$26.75+312.2%+99.4%$475.93MN/A-2.8740STOKStoke Therapeutics3.5849 of 5 stars$8.92-0.9%$21.29+138.6%+89.9%$472.47M$16.74M-4.25100ARCTArcturus Therapeutics2.5077 of 5 stars$17.31-3.7%$66.75+285.6%-48.8%$468.88M$142.47M-7.80180Short Interest ↑RNACCartesian Therapeutics2.05 of 5 stars$18.33+8.8%$42.86+133.8%-15.7%$465.86M$47.94M-0.3564MLYSMineralys Therapeutics2.8502 of 5 stars$9.36-5.2%$30.00+220.5%+5.4%$465.84MN/A-2.8628VERVVerve Therapeutics2.7664 of 5 stars$5.50-0.5%$25.75+368.2%-48.6%$465.65M$24.40M-2.24110MGTXMeiraGTx4.6964 of 5 stars$5.91-4.7%$23.50+297.6%+2.3%$461.88M$13.93M-4.88300Gap UpSAGESage Therapeutics4.6129 of 5 stars$7.50+35.1%$10.53+40.4%-72.8%$458.80M$106.40M-1.34690High Trading Volume Related Companies and Tools Related Companies Altimmune Alternatives ProKidney Alternatives Mind Medicine (MindMed) Alternatives Stoke Therapeutics Alternatives Arcturus Therapeutics Alternatives Cartesian Therapeutics Alternatives Mineralys Therapeutics Alternatives Verve Therapeutics Alternatives MeiraGTx Alternatives Sage Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TELO) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
